ArticleJournal of managed care & specialty pharmacy2026
Timing of health technology assessment in the United States: An evaluation of ICER reviews over 8 years.
Article in Journal of managed care & specialty pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Institute for Clinical and Economic Review (ICER) aims to publish health technology assessment (HTA) reports at or near the time of drug approval by the US Food and Drug Administration (FDA) to provide a timely, independent evaluation of the benefits, risks, and economic considerations surrounding a new therapy.
objectiveTo evaluate the timelines of ICER reports to inform pricing and coverage decisions, using FDA approval and list price announcement dates as a benchmark. With these data, we evaluated the availability of clinical evidence, specifically completion of pivotal trials and publication in peer-reviewed journals, at the time of ICER's review.
methodsWe included drugs that were the primary intervention of interest in ICER reviews between 2017 and 2024. We extracted information on regulatory approval and list price announcements, and publication dates of ICER reports. We also extracted dates of publication of the pivotal trials that informed each ICER assessment to evaluate the time span between trial completion and publication.
resultsOur analysis of 73 ICER drug assessments showed that, on average, the launch price is announced on the same day as FDA approval. The majority of the ICER draft, evidence, and final assessments were published on or before the FDA approval and price announcement date (82%, 61%, 55%, respectively). In terms of data availability, the median time from primary trial completion to peer-review publication was 15 months. There were an average of 2 pivotal trials per drug assessment. The majority (71%) of the pivotal trials informing ICER assessments were published in peer-reviewed journals before the completion of the ICER draft assessment, although these publications were, on average, published approximately 1 month prior to the completion of the assessments.
conclusionsThe majority of ICER drug assessments are published before FDA approval and price announcements, making them available for early decision-making at the time of drug launch. However, data availability is still a major challenge in making HTA available immediately after approval. Prioritizing early sharing of clinical trial data would foster timely and robust HTA, ensure clinical decisions and coverage policies are well informed, and improve early patient access.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.